Creative Medical Technology Holdings (CELZ) Interest Expenses (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Interest Expenses of -$50.0 for Q2 2023, down 200.0% quarter-over-quarter from $50.0 in Q1 2023.
Creative Medical Technology Holdings (CELZ) Interest Expenses (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Interest Expenses for 14 consecutive years, with -$50.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Interest Expenses changed N/A year-over-year to -$50.0; the TTM figure through Mar 2024 stood at -$50.0 (up 99.45% YoY), while the FY2025 annual figure was $9.2 million, up 20.55% from the prior year.
- Interest Expenses fell to -$50.0 in Q2 2023 per CELZ's latest filing, from $50.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $2.4 million in Q4 2021 and bottomed at -$9186.0 in Q3 2022.
- Historically, Interest Expenses has averaged $570521.6 across 5 years, with a median of $323223.0 in 2020.
- Annual changes were most pronounced in 2021 — Interest Expenses soared 351.32% — and 2022, when it slumped 100.7%.
- Creative Medical Technology Holdings' Interest Expenses stood at $1.9 million in 2019, then slumped by 84.63% to $289210.0 in 2020, then soared by 730.8% to $2.4 million in 2021, then plunged by 100.38% to -$9186.0 in 2022, then surged by 99.46% to -$50.0 in 2023.
- Business Quant data shows CELZ's Interest Expenses at -$50.0 in Q2 2023, $50.0 in Q1 2023, and -$9186.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5,500.00 |
| Jun 30, 2026 | 5,500.00 |
| Jun 30, 2023 | -50.00 |
| Jun 30, 2023 | -50.00 |
| Mar 31, 2023 | 50.00 |
| Mar 31, 2023 | 50.00 |
| Sep 30, 2022 | -9,186.00 |
| Sep 30, 2022 | -9,186.00 |
| Mar 31, 2022 | 9,186.00 |
| Mar 31, 2022 | 9,186.00 |
| Dec 31, 2021 | 2.40 Mn |
| Dec 31, 2021 | 2.40 Mn |
| Sep 30, 2021 | 1.31 Mn |
| Sep 30, 2021 | 1.31 Mn |
| Jun 30, 2021 | 234,338.00 |
| Jun 30, 2021 | 234,338.00 |
| Mar 31, 2021 | 336,076.00 |
| Mar 31, 2021 | 336,076.00 |
| Sep 30, 2020 | 289,210.00 |
| Sep 30, 2020 | 289,210.00 |